Corrigendum: A combination of metformin and epigallocatechin gallate potentiates glioma chemotherapy in vivo

Shreyas S Kuduvalli; Precilla S Daisy; Anandraj Vaithy; Mugilarasi Purushothaman; Arumugam Ramachandran Muralidharan; Kumar B Agiesh; Markus Mezger; Justin S Antony; Madhu Subramani; Biswajit Dubashi; Indrani Biswas; K P Guruprasad; T S Anitha

doi:10.3389/fphar.2023.1322332

Corrigendum: A combination of metformin and epigallocatechin gallate potentiates glioma chemotherapy in vivo

Front Pharmacol. 2024 Jan 9:14:1322332. doi: 10.3389/fphar.2023.1322332. eCollection 2023.

Affiliations

¹ Mahatma Gandhi Medical Advanced Research Institute (MGMARI), Sri Balaji Vidyapeeth University (Deemed to-be University), Puducherry, India.
² Department of Pathology, Mahatma Gandhi Medical College and Research Institute, Sri Balaji Vidyapeeth University (Deemed to-be University), Puducherry, India.
³ Department of Pharmacy, National University of Singapore, Singapore, Singapore.
⁴ Department of Visual Neurosciences, Singapore Eye Research Institute, Singapore, Singapore.
⁵ Eye-APC, Duke-NUS Medical School, Singapore, Singapore.
⁶ Department of General Paediatrics, Haematology/Oncology, University Children's Hospital Tübingen, Tübingen, Germany.
⁷ ScirosBio (FZC), SRTI Park, Sharjah, United Arab Emirates.
⁸ Department of Medical Oncology, Jawaharlal Institute of Postgraduate Medical Education and Research (JIPMER), Puducherry, India.
⁹ Department of Ageing Research, Manipal School of Life Sciences, MAHE, Manipal, Karnataka, India.

Abstract

[This corrects the article DOI: 10.3389/fphar.2023.1096614.].

Keywords: PI3K/Akt/mTOR pathway; ROS-reactive oxygen species; epigallocatechin gallate (EGCG); glioma; metformin; molecular docking; quantum mechanics (QM).

Publication types

Published Erratum